health-innovation
(3)
David Schummers
David Schummers is the co-founder and CEO of Apella Technology, a San Francisco-based ambient AI company transforming how hospitals run their operating rooms. Using computer vision and machine learning, Apella captures real-time surgical intelligence - automatically documenting up to 14 case events per procedure and feeding structured data back into EHR systems - reducing OR turnover times by 16% and increasing case volume by 10%. Before founding Apella in 2019, Schummers spent two decades in health technology, including a pivotal stint at Auris Health as its first commercial executive, where he helped engineer the company's $5.7 billion acquisition by Johnson & Johnson in 2019 - at the time the largest medical technology startup transaction in history. Apella raised an $80 million Series B in January 2026 led by HighlandX, bringing total funding to over $104 million.
Sach Jain
Sach Jain is the Founder & CEO of Carrum Health, a San Francisco-based value-based care platform that connects self-insured employers with top-tier hospitals and surgical centers through bundled payment arrangements. Founded in 2014 after Jain's frustration with America's fee-for-service healthcare system, Carrum Health has raised $96M in total funding and now covers 90% of the US population through a network that includes Mayo Clinic, Cleveland Clinic, Johns Hopkins, and Stanford. With a background spanning IIT Delhi, University of Chicago Booth, investment banking at Bank of America Merrill Lynch, and healthcare consulting at Booz & Company, Jain built Carrum to solve a systemic problem: employers spending $20,000+ per employee annually on health benefits with up to a 10x pricing variation for identical procedures.
Rick Winningham
Rick Winningham is the CEO of Theravance Biopharma, a biopharmaceutical company focused on organ-selective medicines for serious diseases including COPD, rare neurological conditions, and inflammatory diseases. With over 40 years in the pharmaceutical industry - including 13 years as CEO of Innoviva and 15 years at Bristol-Myers Squibb - Winningham has built a career defined by transformative drug development, strategic company leadership, and a widely recognized commitment to mentoring the next generation of biopharma executives, particularly women in leadership. He was named the 2026 HBA Honorable Mentor by the Healthcare Businesswomen's Association.